Price History
Feb 9, 2026 — Jul 8, 2026Investment Snapshot
- Trading 91% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 11.2% — below-average profitability
- Revenue growing at 6% annually
Abbott Laboratories Common Stock (ABT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $157.6 billion . Key value metrics: P/E ratio 27.1, P/B ratio 3.03, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Abbott Laboratories Common Stock — Fundamental Analysis Summary
Abbott Laboratories Common Stock (ABT) is currently trading 91% above its Graham Number of $47.42, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 27.1x.
On financial health, ABT shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 11.2% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.57.
StockPik's composite Value Score for ABT is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ABT reports a solid gross margin of 56.2% (sector average: 39.4%) and a solid operating margin of 16.2%.
ABT shows revenue growing at 6% year-over-year, with earnings declining at 51%.
ABT pays a modest dividend yield of 2.7%.